Skip to main content
Top
Published in: Journal of General Internal Medicine 4/2022

01-03-2022 | Buprenorphine | Original Research

Impact of High Deductible Health Plans on Continuous Buprenorphine Treatment for Opioid Use Disorder

Authors: Alene Kennedy-Hendricks, PhD, Cameron J. Schilling, MPH, Alisa B. Busch, MD, MS, Elizabeth A. Stuart, PhD, Haiden A. Huskamp, PhD, Mark K. Meiselbach, BS, Colleen L. Barry, PhD, MPP, Matthew D. Eisenberg, PhD

Published in: Journal of General Internal Medicine | Issue 4/2022

Login to get access

Abstract

Background

Long-term, continuous treatment with medication like buprenorphine is the gold standard for opioid use disorder (OUD). As high deductible health plans (HDHPs) become more prevalent in the commercial insurance market, they may pose financial barriers to people with OUD.

Objective

To estimate the impact of HDHPs on continuity of buprenorphine treatment, concurrent visits for counseling/psychotherapy and OUD-related evaluation and management, and out-of-pocket spending.

Design

Difference-in-differences analysis comparing trends in outcomes among enrollees whose employers offer an HDHP (treatment group) to enrollees whose employers never offer an HDHP (comparison group).

Participants

Enrollees with OUD from a national sample of commercial health insurance plans during 2007–2017 who initiate buprenorphine treatment.

Main Measures

Number of days of continuous buprenorphine treatment; probabilities of continuous buprenorphine treatment ≥30, ≥90, ≥180, and ≥365 days; probability of concurrent (i.e., within the same month) behavioral therapy (i.e., counseling or psychotherapy); probability of concurrent OUD-related evaluation and management visits; proportions of buprenorphine treatment episodes with counseling/psychotherapy and evaluation and management visits; and out-of-pocket (OOP) spending on buprenorphine, behavioral therapy, and evaluation and management visits.

Key Results

HDHPs were associated with an average increase of $98 (95% CI: $48, $150) on OOP spending on buprenorphine per treatment episode but no change in the number of days of continuous buprenorphine treatment or concurrent use of related services.

Conclusions

HDHPs do not reduce continuity of buprenorphine treatment among commercially insured enrollees with OUD but may increase financial burden for this population.
Appendix
Available only for authorised users
Literature
6.
go back to reference Schwartz RP, Gryczynsi J, O’Grady KE, et al. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009. Am J Public Heal. 2013;103(5):917-922.CrossRef Schwartz RP, Gryczynsi J, O’Grady KE, et al. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009. Am J Public Heal. 2013;103(5):917-922.CrossRef
9.
go back to reference Krawczyk N, Mojtabai R, Stuart EA, et al. Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services. Addiction. 2020;115(9). Krawczyk N, Mojtabai R, Stuart EA, et al. Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services. Addiction. 2020;115(9).
15.
go back to reference Fiellin DA, Schottenfeld R, Cutter C, Moore B, Barry D, O’Connor P. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. JAMA Intern Med. 2014;174(12):1947-1954.CrossRef Fiellin DA, Schottenfeld R, Cutter C, Moore B, Barry D, O’Connor P. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. JAMA Intern Med. 2014;174(12):1947-1954.CrossRef
23.
go back to reference Eisenberg MD, Kennedy-Hendricks A, Schilling CJ, Busch AB, Huskamp HA, Stuart EA, Meiselbach M, Barry CL. The impact of high deductible health plans on service use and spending for substance use disorders. Under review Eisenberg MD, Kennedy-Hendricks A, Schilling CJ, Busch AB, Huskamp HA, Stuart EA, Meiselbach M, Barry CL. The impact of high deductible health plans on service use and spending for substance use disorders. Under review
28.
go back to reference Abdus S. The role of plan choice in health care utilization of high-deductible plan enrollees. Heal Serv Res. 2020;55(1):119-127.CrossRef Abdus S. The role of plan choice in health care utilization of high-deductible plan enrollees. Heal Serv Res. 2020;55(1):119-127.CrossRef
29.
go back to reference Kullgren J, Volpp K, Polsky D. Are the healthy behaviors of US high-deductible health plan enrollees driven by people who chose these plans? Smoking as a case study. PLoS One. 2013;8(2):e56154.CrossRef Kullgren J, Volpp K, Polsky D. Are the healthy behaviors of US high-deductible health plan enrollees driven by people who chose these plans? Smoking as a case study. PLoS One. 2013;8(2):e56154.CrossRef
32.
33.
go back to reference Centers for Medicare & Medicaid Services. CMS Chronic Conditions Data Warehouse. www2.ccwdata.org. Published 2020. Accessed February 1, 2020. Centers for Medicare & Medicaid Services. CMS Chronic Conditions Data Warehouse. www2.​ccwdata.​org. Published 2020. Accessed February 1, 2020.
35.
go back to reference Belotti F, Deb P, Manning WG, Norton EC. twopm: Two-part models. Stata J. 2015;15(1):3-20. The Stata JournalCrossRef Belotti F, Deb P, Manning WG, Norton EC. twopm: Two-part models. Stata J. 2015;15(1):3-20. The Stata JournalCrossRef
36.
go back to reference StataCorp. Stata Statistical Software: Release 16. 2019. StataCorp. Stata Statistical Software: Release 16. 2019.
Metadata
Title
Impact of High Deductible Health Plans on Continuous Buprenorphine Treatment for Opioid Use Disorder
Authors
Alene Kennedy-Hendricks, PhD
Cameron J. Schilling, MPH
Alisa B. Busch, MD, MS
Elizabeth A. Stuart, PhD
Haiden A. Huskamp, PhD
Mark K. Meiselbach, BS
Colleen L. Barry, PhD, MPP
Matthew D. Eisenberg, PhD
Publication date
01-03-2022
Publisher
Springer International Publishing
Published in
Journal of General Internal Medicine / Issue 4/2022
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-021-07094-9

Other articles of this Issue 4/2022

Journal of General Internal Medicine 4/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.